Anti-calcitonin gene-related peptide treatments in women's health: Gaps and clinical evidence in menstrual-related migraine, pregnancy, lactation, and hormonal contraception: A narrative review.

This research paper reviews the use of anti-calcitonin gene-related peptide (CGRP) treatments for women. It focuses on menstrual-related migraines and their impact during pregnancy, lactation, and while using hormonal contraception. Migraines affect women more than men, especially during reproductive years. Hormonal changes can influence migraine susceptibility by affecting CGRP signaling. Although anti-CGRP therapies like monoclonal antibodies and gepants have proven effective, there is limited evidence on their safety and efficacy in these specific reproductive contexts. The researchers conducted a systematic search of medical databases to find relevant studies. They screened studies independently to gather data on CGRP treatments and women's health. The findings highlight the need for more research to understand how these therapies can be safely used in pregnant women and those who are breastfeeding. This could lead to better migraine management for women during these important life stages. Clinical relevance: This research underscores the need for more evidence on CGRP therapies in women's reproductive health to ensure safe and effective migraine treatment during pregnancy and lactation.